Alnylam Pharmaceuticals Inc., a Cambridge company looking to develop therapeutics based on RNA interference, said it has restructured its relationship with Tekmira Pharmaceuticals with a new licensing agreement. It also said the companies have resolved all litigation between them. Tekmira will receive $65 million, and is eligible to receive $10 million in near-term milestone payments. The litigation involved intellectual property rights of lipid nanoparticle technology, Tekmira said.
Unlimited access to BostonGlobe.com for only 99 cents for the first 4 weeks.Sign up
Are you a home delivery subscriber?
Get FREE access as part of your print subscriptionStart Here
Contact us for help